Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis
- 751 Downloads
To investigate the therapeutic effect of methylselenocysteine (MSC) combined with tamoxifen in MCF-7 breast cancer xenograft and the underlying mechanisms. MCF-7 breast cancer xenograft was established in ovariectomized female athymic nude mice and treated with tamoxifen and/or MSC. Tumor size was measured twice a week. Immunohistochemistry and TUNEL assays were used to measure ERα expression, ERα target genes (progesterone receptor (PR) and cyclin D1 expression), Ki-67 index, apoptosis and microvessel density. Combined treatment with tamoxifen and MSC synergistically inhibited tumor growth compared to MSC alone and tamoxifen alone. MSC alone or MSC + tamoxifen significantly reduced ERα, PR and cyclin D1, Ki67 index and microvessel density while increasing apoptosis in tumor tissues. These findings demonstrate synergistic growth inhibition of ERα positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds. Organic selenium may provide added benefit when combined with tamoxifen in adjuvant therapy or prevention.
KeywordsBreast cancer Xenograft Synergy Selenium Tamoxifen Apoptosis Proliferation Angiogenesis
Estrogen receptor α
Prostate specific antigen
Poly ADP-ribose polymerase
Terminal DNA transferase-mediated dUTP nick end labeling
This project was supported, in part, by grants from the Louisiana Cancer Research Consortium to BGR.
- 6.Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 276:1957–1963. doi: 10.1001/jama.276.24.1957 CrossRefPubMedGoogle Scholar
- 12.Lee SO, Yeon Chun J, Nadiminty N et al (2006) Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66:1070–1075. doi: 10.1002/pros.20329 CrossRefPubMedGoogle Scholar
- 27.Jiang C, Jiang W, Ip C et al (1999) Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 26:213–225. doi:10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-ZGoogle Scholar
- 30.Rustum Y, Cao S, Durrani F et al (2004) Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity of irinotecan against human tumor xenografts and protects against drug induced toxicity. J Clin Oncol 22:2068 (meeting abstracts)Google Scholar